Drug Profile
Naloxone controlled release - Algobate
Alternative Names: Naloxone extended release; Naloxone prolonged release; NLX PRT; NLX-PRLatest Information Update: 29 Nov 2022
Price :
$50
*
At a glance
- Originator Algobate AG; Develco Pharma Schweiz
- Class Antidotes; Behavioural disorder therapies; Benzofurans; Drug withdrawal therapies; Isoquinolines; Ketones; Laxatives; Morphinans; Small molecules
- Mechanism of Action Opioid mu receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Constipation
Highest Development Phases
- Phase III Constipation
Most Recent Events
- 28 Nov 2022 No development reported - Phase-III for Constipation in Portugal (PO) (NCT03687268)
- 27 Oct 2020 No development reported - Phase-III for Constipation in Bulgaria, Serbia, Poland (PO) (NCT03687268)
- 02 May 2020 Develco Pharma Schweiz completes the phase III NAXOS trial in Constipation in Czech Republic, Germany, Hungary, Poland, Portugal, Slovakia, Spain and the UK (PO) (EudraCT2017-000657-39)